Published in Vaccine Weekly, April 10th, 1995
Called the T7-T7 gene expression system and developed by Progenitor Inc., Athens, Ohio, the plasmid acts as an artificial retrovirus. It can be directly injected into tissues where it enters the cytoplasm of target cells. Unlike a normal retrovirus, the T7 plasmid does not enter the cell nucleus and therefore does not depend upon the cellular replicative machinery for expression.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly